Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$42 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.8
Industry P/E
22.97
EV/EBITDA
-3.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-6.1
Face value
--
Shares outstanding
16,253,300
CFO
$-151.84 Mln
EBITDA
$-186.70 Mln
Net Profit
$-149.28 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Jasper Therapeutics (JSPR)
| -88.6 | -7.6 | -56.6 | -88.2 | -50.1 | -52.4 | -- |
|
BSE Sensex
| 4.7 | 1.6 | -0.7 | 0.5 | 11.1 | 16.1 | 12.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Jasper Therapeutics (JSPR)
| 168.8 | 63.4 | -93.8 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Jasper Therapeutics (JSPR)
|
2.4 | 42.1 | 1.2 | -90.9 | -7,737.0 | -213.5 | -- | 1.8 |
| 16.1 | 3,911.2 | 474.2 | 208.9 | 32.7 | 55.9 | 19.3 | 9.8 | |
| 24.9 | 3,389.6 | 754.7 | -228.2 | -23.9 | -118.6 | -- | 21.7 | |
| 44.7 | 6,181.8 | 10.7 | -455.7 | -4,870.9 | -34.8 | -- | 5.2 | |
| 118.4 | 6,271.6 | 495.0 | -246.9 | -39.8 | -379.6 | -- | 85.8 | |
| 54.1 | 10,693.3 | 3,063.6 | 657.2 | 27.6 | 11.2 | 16.4 | 1.8 | |
| 51.2 | 10,227.5 | 235.8 | -776.4 | -275.3 | -- | -- | 123.7 | |
| 72.9 | 7,558.3 | 716.1 | 132.5 | 14.2 | 20.1 | 64 | 11.9 | |
| 18.5 | 9,320.2 | 4,484.0 | 434.0 | 19.2 | 6.7 | 21.3 | 1.4 | |
| 10.0 | 12,183.3 | 14,115.7 | -3,468.3 | -23.0 | -20.3 | -- | 0.8 |
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to... block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California. Address: 2200 Bridge Pkwy, Redwood City, CA, United States, 94065 Read more
President, CEO & Director
Mr. Ronald A. Martell
President, CEO & Director
Mr. Ronald A. Martell
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Jasper Therapeutics Inc (JSPR) is $2.43 (NASDAQ) as of 12-Sep-2025 16:06 EDT. Jasper Therapeutics Inc (JSPR) has given a return of -50.14% in the last 3 years.
Since, TTM earnings of Jasper Therapeutics Inc (JSPR) is negative, P/E ratio is not available.
The P/B ratio of Jasper Therapeutics Inc (JSPR) is 1.79 times as on 10-Sep-2025, a 64 discount to its peers’ median range of 5.04 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-4.50
|
5.20
|
|
2023
|
-0.12
|
0.10
|
|
2022
|
-0.05
|
0.05
|
|
2021
|
-1.02
|
0.45
|
|
2020
|
-0.32
|
1.15
|
The 52-week high and low of Jasper Therapeutics Inc (JSPR) are Rs 26.05 and Rs 2.27 as of 13-Sep-2025.
Jasper Therapeutics Inc (JSPR) has a market capitalisation of $ 42 Mln as on 10-Sep-2025. As per Value Research classification, it is a Small Cap company.
Before investing in Jasper Therapeutics Inc (JSPR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.15
(
